Expression of topoisomerase II, BCL-2, and Ki-67 in ovarian cancer tissue and their effects on the development and prognosis of ovarian cancers

Erişim
info:eu-repo/semantics/closedAccessTarih
2017Yazar
Akyürek, E. N.Avşar, Ayşe Filiz Yavuz
Ural, Ülkü Mete
Kılıçarslan, Ahmet Faruk
Yıldırım, Melahat
Üst veri
Tüm öğe kaydını gösterKünye
Akyürek, E.N., Avşar, A.F.Y., Ural, Ü.M., Kılıçarslan, A. & Yıldırım, M. (2017). Expression of topoisomerase II, BCL-2, and Ki-67 in ovarian cancer tissue and their effects on the development and prognosis of ovarian cancers. European Journal of Gynaecological Oncology, 38(5), 675-679. https://doi.org/10.12892/ejgo3370.2017Özet
Purpose: the objective of this study was to evaluate the role of the expression of topoisomerase II, BCL-2, and Ki-67 in an ovarian tissue and their effects on the development and the prognosis of ovarian cancers. Materials and Methods: the study consisted of 38 female patients with ovarian cancers. Patients' characteristics, tumor type, stage, and the grade of the disease, and topoisomerase II, Bcl2, and Ki-67 values in ovarian tissue were compared. Results: Extensivenesses of topoisomerase II and Ki-67 staining in early -stage disease were found statistically different from those in the advanced stage diseases (for topoisomerase II, 60.38 33.87% vs 85 8.5%, p = 0.017, for Ki-67; 25.07 +/- 25.04% vs 51 +/- 25.29%,p = 0.012). Differences of Bcl-2 staining between two groups were not significant (30.38 +/- 38.82 % vs 18.2 +/- 30.58%, p = 0.377). Conclusions: Expressions of topoisomerase II and Ki-67 in ovarian cancer tissues were associated with advanced stage diseases and expression of Bcl-2 refers to good histological grade in patients.